<DOC>
	<DOCNO>NCT02191176</DOCNO>
	<brief_summary>The primary objective current study investigate safety special emphasis ECG effect , tolerability dextromethorphan hydrobromide monohydrate ( 2mg/mL syrup ) healthy male female subject follow oral administration 30 mg q.i.d . 90 mg q.i.d . 2 day follow single morning dose ( extensive metabolisers CYP 2D6 ) 10 day follow single morning dose ( poor metabolisers CYP 2D6 ) . Additionally pharmacokinetic property dextromethorphan main metabolite dextrorphan , 3-hydroxymorphinan , 3-methoxymorphinan investigate</brief_summary>
	<brief_title>Study Investigate Safety With Special Emphasis ECG Effects Tolerability After Oral Doses Dextromethorphan Hydrobromide Monohydrate Healthy Male Female Subjects</brief_title>
	<detailed_description />
	<mesh_term>Dextromethorphan</mesh_term>
	<criteria>Healthy male female accord follow criterion : Based upon complete medical history , include physical examination , oral body temperature , vital sign ( blood pressure , pulse rate ) , 12lead Electrocardiogram ( ECG ) , clinical laboratory test Age ≥18 Age ≤55 year BMI ≥18.5 BMI ≤30 kg/m2 ( Body Mass Index ) Extensive poor metabolisers CYP 2D6 base result genotyping test Signed date write informed consent prior admission study accordance Good Clinical Practice ( GCP ) local legislation Any finding medical examination ( include blood pressure , pulse rate ECG ) deviate normal clinical relevance Any evidence clinically relevant concomitant disease Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder Surgery gastrointestinal tract ( except appendectomy ) Diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder History relevant orthostatic hypotension , faint spell blackouts Chronic relevant acute infection History relevant allergy/hypersensitivity ( include allergy drug excipients ) Intake drug long halflife ( &gt; 24 hour ) within least one month le 10 halflives respective drug prior administration trial Use drug might reasonably influence result trial prolong QT/QTc interval base knowledge time protocol preparation within 10 day prior administration trial Participation another trial investigational drug within one month prior first administration trial Smoker ( &gt; 10 cigarette &gt; 3 cigar &gt; 3 pipes/day ) Inability refrain smoke trial day Alcohol abuse ( 60 g/day ) Drug abuse Blood donation ( 100 mL within four week prior first administration trial ) Excessive physical activity ( within one week prior first administration trial ) Any laboratory value outside reference range clinical relevance Inability comply dietary regimen trial site A marked baseline prolongation QTc interval &gt; 450 m ; A history additional risk factor Torsades de point ( e.g. , heart failure , hypokalemia , family history Long QT Syndrome ) Exclusion criterion specific study : Use drug inhibit induce cytochrome P 450 enzyme , especially CYP2D6 , within 30 day prior first administration study medication trial For female subject : Pregnancy plan become pregnant within 2 month study completion Positive pregnancy test No adequate contraception woman child bear potential study , i.e. , sterilisation , intrauterine device , injectables , oral contraceptive combine barrier method contraception Lactation period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>